214 related articles for article (PubMed ID: 14604740)
1. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.
Barbaro G; Di Lorenzo G; Cirelli A; Grisorio B; Lucchini A; Hazra C; Barbarini G
Clin Ther; 2003 Sep; 25(9):2405-18. PubMed ID: 14604740
[TBL] [Abstract][Full Text] [Related]
2. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
[TBL] [Abstract][Full Text] [Related]
3. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
4. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
[TBL] [Abstract][Full Text] [Related]
6. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
Gonzalez-Tome MI; Amador JT; Peña MJ; Gomez ML; Conejo PR; Fontelos PM
BMC Infect Dis; 2008 Oct; 8():144. PubMed ID: 18945352
[TBL] [Abstract][Full Text] [Related]
7. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
9. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
10. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.
Ceccato MG; Bonolo PF; Souza Neto AI; Araújo FS; Freitas MI
Braz J Med Biol Res; 2011 Nov; 44(11):1177-83. PubMed ID: 22052375
[TBL] [Abstract][Full Text] [Related]
12. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor.
Calista D; Morri M; Stagno A; Boschini A
Am J Clin Dermatol; 2002; 3(1):59-62. PubMed ID: 11817969
[TBL] [Abstract][Full Text] [Related]
13. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors.
Coplan PM; Nikas A; Japour A; Cormier K; Maradit-Kremers H; Lewis R; Xu Y; DiNubile MJ
AIDS Res Hum Retroviruses; 2003 Jun; 19(6):449-55. PubMed ID: 12882653
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
Bruyand M; Ryom L; Shepherd L; Fatkenheuer G; Grulich A; Reiss P; de Wit S; D Arminio Monforte A; Furrer H; Pradier C; Lundgren J; Sabin C;
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):568-77. PubMed ID: 25763785
[TBL] [Abstract][Full Text] [Related]
15. Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort.
Maggiolo F; Ripamonti D; Airoldi M; Callegaro A; Arici C; Ravasio V; Bombana E; Goglio A; Suter F
HIV Clin Trials; 2007; 8(1):9-18. PubMed ID: 17434844
[TBL] [Abstract][Full Text] [Related]
16. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
Crane HM; Van Rompaey SE; Kitahata MM
AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
[TBL] [Abstract][Full Text] [Related]
17. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.
Galli M; Ridolfo AL; Adorni F; Gervasoni C; Ravasio L; Corsico L; Gianelli E; Piazza M; Vaccarezza M; d'Arminio Monforte A; Moroni M
J Acquir Immune Defic Syndr; 2002 Jan; 29(1):21-31. PubMed ID: 11782586
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and management of dyslipidemia in patients with HIV infection.
Green ML
J Gen Intern Med; 2002 Oct; 17(10):797-810. PubMed ID: 12390557
[TBL] [Abstract][Full Text] [Related]
19. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
Senise JF; Castelo A; Martínez M
AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
[TBL] [Abstract][Full Text] [Related]
20. Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review.
Silva BF; Peixoto G; da Luz SR; de Moraes S; Peres SB
HIV Med; 2019 Aug; 20(7):429-438. PubMed ID: 31006976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
